Prenatal serological diagnosis of intrauterine cytomegalovirus infection
Cytomegalovirus commonly causes intrauterine infection. Finding a primary or reactivated cytomegalovirus infection in the mother by isolating the virus from the throat, urine, cervix, or blood, or by maternal serology, does not necessarily indicate that the fetus will be infected. Fetal infection appears to occur in no more than 25-50% of even primary maternal infections. The presence of intrauterine infection has been established by culture of cytomegalovirus from amniotic fluid,' but such isolation may be time consuming. We report a case that shows that the availability of a sensitive radioimmunoassay for the detection of cytomegalovirus-specific JgM2 and the ability to obtain fetal cord serum3 mean that intrauterine serological diagnosis is possible.
Case report
A 28-year-old rhesus-positive woman without atypical antibodies was referred at 25 weeks' gestation after ultrasonography showed a hydropic fetus. She had felt well throughout the pregnancy, denied taking any medication, and reported no relevant personal or family history. At 16 weeks' gestation an ultrasound scan had confirmed her dates and shown no major structural abnormalities. Examination was unremarkable, with fundal height being consistent with dates. A further ultrasound scan confirmed a single fetus with gross ascites, but no other abnormalities were observed. Fetoscopy was carried out and 8 ml pure fetal blood and 260 ml ascitic fluid collected. Fetal serum showed appreciable hypoalbuminaemia of 6 g/l (normal 21± SD 2 g/l (unpublished)). A fetal blood film showed severe erythroblastosis.
A follow-up ultrasound scan showed re-collection of the ascites. Intravascular fetal albumin infusion was planned but precluded by spontaneous premature rupture of the membranes at 27 weeks' gestation. A conservative policy was adopted but labour ensued and a 1480 g severely depressed male infant delivered. Resuscitative attempts were stopped after 20 minutes.
Initial serology for cytomegalovirus on maternal sera showed an antibody titre of 32 when a complement fixation test was performed on sera collected at 21 weeks' and 25 weeks' gestation. No cytomegalovirus-specific IgM was detected in the fetal serum using indirect immunofluorescence (Electronucleonics Laboratories Inc, Maryland, USA).
Necropsy showed non-icteric hydrops fetalis (figure). Macroscopically the only abnormal findings were a large liver with a finely nodular and mottled surface and massive ascites causing gross elevation of the diaphragm with consequent pulmonary hypoplasia. Microscopy showed cytomegaly and intranuclear "owl's eye" inclusions in many organs, particularly the kidney (figure). The appearance was typical of cytomegalic inclusion disease. The liver showed extreme active erythropoiesis. Cytomegalovirus was isolated from urine obtained at necropsy. These findingsprompted a re-examination of stored maternal andfetal cord sera. The total IgM content of the fetal serum was 0 11 g/l. This is within the normal range for a fetus of this gestation as stated by Alford et al. 4 Radioimmunoassay for cytomegalovirus IgM showed that the fetal serum had a titre of 4000. This is within the range seen in neonatal or cord serum from confirmed cases of symptomatic congenital cytomegalovirus.5 Examination of the maternal serum for cytomegalovirus-specific IgM by radioimmunoassay showed a titre of 800 in the serum taken at 21 weeks' gestation, but such IgM was absent at 25 weeks. These results were compatible with a primary infection occurring early in the pregnancy.
Comment
Cytomegalovirus is a recognised cause of hydrops fetalis, and intrauterine cytomegalovirus infection was confirmed in this case by histology and isolation of the virus. Initial serology for cytomegalovirus specific IgM on fetal cord serum obtained at 25 weeks' gestation was negative using an indirect fluorescence assay. When a sensitive radioimmunoassay was used, cytomegalovirus-specific IgM was detected with ease, showing the increased sensitivity of this procedure for diagnosing congenital cytomegalovirus.5 We believe this to be the first case in which virus-specific IgM has been shown in fetal serum obtained in utero.
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Requests for reprints should be addressed to CHR. Because of the rapid clearance of doxorubicin from the circulation scalp hypothermia has been used to limit the amount of drug reaching the hair follicles, preventing hair loss. This is particularly effective when total doses are below 50 mg,2-4 but with higher doses results are less certain. We investigated the relation of the scalp skin temperature obtained with hypothermia to the degree of hair loss.
Patients, methods, and results
Scalp cooling was undertaken in 24 patients with breast carcinoma. Of these, 18 were receiving chemotherapy for advanced disease and six adjuvant systemic treatment for primary tumours. Results of liver function tests were normal in all cases. The same drug regimen was used in all 24 patients. Doxorubicin 40 mg/M2 (average dose 60-70 mg) and vincristine 2-0 mg were given intravenously on days 1 and 8 of a four-week cycle. Prednisolone 10 mg was given by mouth for the first 14 days of the cycle.
Scalp skin temperature was measured with a thermocouple constructed from a hypodermic needle, which was introduced into the scalp to a depth of 1-2 mm to be at the approximate level of the hair follicles and remained in place throughout the cooling procedure. To cool the scalp frozen cryogel packs were moulded on to the head and held in place with a plastic helmet. Cooling was maintained until the lowest temperature was reached and doxorubicin then injected. Cooling continued for a further 30 minutes.
Hair loss was categorised as slight, moderate, severe, or complete at the patient's third cycle of chemotherapy.
Scalp temperature in the 24 patients varied from 18-5°C to 28-5°C. In each individual patient, however, a consistent temperature was obtained on repeated measurement. Maximal cooling occurred after 20-30 minutes of hypothermia, which was maintained for 30-40 minutes (figure).
Ten of the 24 patients (420' ) receiving high-dose doxorubicin showed satisfactory hair retention. All these patients suffered slight hair loss but not sufficient for them to require a wig.
The degree of alopecia was temperature dependent. In 19 patients in whom temperature was measured during two cycles of chemotherapy that reached in women who showed good hair retention was significantly lower (p < 0x001) than that reached in those with alopecia (20 8°C v 24 2°C). To prevent alopecia scalp temperature had to be reduced to 22°C or below.
Comment
Altogether 420' of patients showed appreciable hair preservation, compared with 5°0 before scalp cooling was introduced. When frequent pulses of high-dose doxorubicin are used it appears that the scalp temperature must be reduced below 22°C before injection and this temperature maintained for 20 minutes to prevent alopecia. Vincristine contributes to the alopecia, which will not, because of this drug's prolonged clearance, be prevented by hypothermia.
These results compare favourably with those reported by other groups using high-dose regimens.5 The improvement in this study was probably due to the delay in administering the chemotherapy until maximal cooling had been obtained-that is, 20-30 minutes after the initiation of hypothermia. In other studies injection was given after five to 10 minutes of cooling. The degree of alopecia is undoubtedly drug-dose dependent,2 with a much higher proportion of hair preservation occurring at lower dosage regimens of less than 40 mg/M2. 2 The large variation in scalp temperature between patients could not be explained by differences in hair thickness or density of scalp tissue. The degree of cooling obtained in each woman, however, was remarkably consistent at each recording, and differences between patients were therefore not due to changes in procedure.
